CN103536909A - Novel urea nitrogen solid adsorption preparation and preparation method thereof - Google Patents
Novel urea nitrogen solid adsorption preparation and preparation method thereof Download PDFInfo
- Publication number
- CN103536909A CN103536909A CN201310488516.0A CN201310488516A CN103536909A CN 103536909 A CN103536909 A CN 103536909A CN 201310488516 A CN201310488516 A CN 201310488516A CN 103536909 A CN103536909 A CN 103536909A
- Authority
- CN
- China
- Prior art keywords
- preparation
- urea nitrogen
- nitrogen solid
- solid adsorption
- novel urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 61
- 239000007787 solid Substances 0.000 title claims abstract description 18
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000001179 sorption measurement Methods 0.000 title abstract 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 3
- 239000012266 salt solution Substances 0.000 claims abstract description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 15
- 235000010413 sodium alginate Nutrition 0.000 claims description 15
- 229940005550 sodium alginate Drugs 0.000 claims description 15
- 239000000661 sodium alginate Substances 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 11
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000010170 biological method Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 159000000013 aluminium salts Chemical class 0.000 abstract 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000004526 pharmaceutical effect Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 239000008187 granular material Substances 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 230000001447 compensatory effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960002523 mercuric chloride Drugs 0.000 description 2
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a novel urea nitrogen solid adsorption preparation and a preparation method thereof. The novel urea nitrogen solid adsorption preparation provided by the invention is a slow-release nano-preparation which is composed of coated aldehyde oxystarch, human albumi, sodium alga acid as well as soluble calcium salt and an aluminium salt solution which are used as curing agents. The novel urea nitrogen solid adsorption preparation provided by the invention has the benefits that the drug content in unit area is higher; the novel urea nitrogen solid adsorption preparation is convenient for patients to take and good in adaption; compared with the ordinary preparation, the novel urea nitrogen solid adsorption preparation has the characteristics that the action time of the preparation in an intestinal tract is longer, and therefore, the pharmaceutical effect can be well played.
Description
Technical field
The invention belongs to field of medicaments, especially relate to a kind of novel blood urea nitrogen solid absorption preparation and preparation method thereof.
Background technology
Kidney is the important Excretory organ of human body, has excretion interior metabolism product, medicine, poisonous substance and removing toxic substances product, and the function of water, electrolyte, acid-base balance in control agent.In addition, kidney can also be secreted feritin, prostaglandin, erythropoietin, 1, and 25-dihydroxyvitamin D3 etc., so as to regulating the important physiological function of body.Therefore kidney is again a multi-functional organ, and it plays an important role in maintaining human internal environment's stability.When the various causes of disease cause renal function serious hindrance, human internal environment will get muddled, its main manifestations is that metabolite is accumulated in vivo, water, electrolyte and acid base imbalance, and cause a series of pathophysiological change, Here it is chronic renal insufficiency with change and the renal endocrine function obstacle of urine amount and urine matter.
Chronic nephropathy runs down and develops into chronic renal failure, be divided into clinically the fourth phase: (1) compensatory phase serum creatinine 141.4～177.0 micromolars/L(1.6～2.0mg/dl), nephron reduces 20%～25%, fair by compensatory renal excretion and regulatory function, if there is albuminuria, patient rises morning can slight blepharoedema, but general without obvious subjective symptoms.(2) lose the compensatory phase (being azotemia phase) serum creatinine 185.9～442.6mmol/L(2.1～5.0mg/dl), nephron reduces 50%～70%, renal excretion and regulatory function go down, and occur frequent urination at night, weak, edema, loss of appetite, feel sick and anemia, occasionally have acidosis.(3) lose (preuremic stage of being) serum creatinine >442.6～708.2 micromolar/L(5.0～8.0mg/dl in compensatory late period), nephron reduces 70%～90%, patient often has serious anemia, edema, can have nauseating, vomiting, metabolic acidosis, hypocalcemia and hyperphosphatemia.(4) Uremic serum creatinine >708.2 micromolar/liter (8.0mg/dl), whole body poisoning symptom is serious, there is large water gaging to store up and stay in vivo more, show as severe edema, often with hydrothorax and ascites, need to rely on dialysis therapy to sustain life, how because hyperpotassemia or acidosis or serious anemia or anuria cause that heart failure or pulmonary edema, cerebral edema are dead.
The absorption preparations such as oral Oxytarch are the method for conventional therapy renal insufficiency, and blood urea nitrogen is declined.Oxytarch can reduce blood urea nitrogen in intestinal absorption and reach 30%.Aldehyde radical (CHO), the nitrogen molecular in-CHO and amide or basic nitrogen compound has affinity, can form with it covalent bond form and be combined into schiff base complex, from feces, discharge, reduce refuse and the poisonous substances such as the interior non-albumen of body, play compensatory renal function, alleviate the effect of kidney burden.Sodium alginate is as slow releasing agent, its site of action occurs at intestinal, under pH=7-9 condition, this drug system absorbs moisture in intestinal, separate out sodium alginate, sodium alginate viscosity is larger, in intestinal, flow slowly, medicine time of staying in intestinal is lengthened, and fully to adsorb nitrogen and the ammonia in intestinal, but the consumption of this slow releasing capsule every day is also wanted 16-48 grain, bring very large inconvenience to patient's medication, especially the patient of bad adaptability, studies and finds that particle diameter is at the medicine of 20-50nm, the most easily by intestinal absorption.
Summary of the invention
The object of this invention is to provide a kind of novel blood urea nitrogen solid absorption preparation and preparation method thereof, the granule that the solid preparation in the present invention is slow release nanometer, its technical scheme is as follows:
A kind of novel blood urea nitrogen solid absorption preparation and preparation method thereof, by containing Coated Aldehyde Oxystarch, human albumin, sodium alginate, and as soluble calcium salt, the aluminum salt solution of firming agent.
(1) material dissolution
Weight ratio is Coated Aldehyde Oxystarch 50-60%, and human albumin is 1-30%, and sodium alginate 1-20%, is dissolved in water for injection.
Native albumin or the biological method preparation of described human albumin for extracting, the purity of human albumin is greater than 99.9%.
(2) grind
The material having dissolved is fully ground, and lapping mode can be selected one or several in cell grinder, Ultrasonic Cell Disruptor, cell crushing instrument, and material need grind above through 3 times, and operation should be carried out at low temperatures.
(3) particle size determination
Ground material carries out the mensuration of nanometer particle size, and nanometer particle size reaches 20-50nm.
(4) lyophilizing
Particle diameter reaches the granule of 20-50nm, is positioned over-80 ℃ of refrigerators and carries out pre-freeze, then by freezer dryer, carry out the freezing of 72h left and right, finally forms crystalloid powder.
(5) be prepared into preparation
Nano level solid particle is prepared into capsule or powder.
(6) pharmacological experiment
Using rat as experimental animal models, the freezing kidney chronic kidney hypofunction of rat model, rat mercuric chloride kidney acute renal failure model, capsule or the powder of feeding in the present invention, to feeding under these oral formulations 3 g preparation/100g body weight of administration, 1g preparation/100g body weight, 0.5g preparation/100g body weight dosage, every day 2 times, after continuous 1 week, blood biochemical detects the content of rat blood serum blood urea nitrogen (BUN), creatinine (Scr).
(7) using methylene blue as indicator, the solid preparation detecting in the present invention is compared the soak time in intestinal with ordinary preparation.
The solid preparation of the sustained-release nano of Coated Aldehyde Oxystarch prepared by the present invention, makes the content of dispersion of unit are larger, takes medicine convenient for patient, better adaptability, and compare with ordinary preparation, said preparation is longer in the action time of intestinal, can better bring into play effect.
Accompanying drawing explanation
Fig. 1, Fig. 2 take simulated gastric fluid, intestinal juice to be measured the dissolution curve chart of gained granule I, II, III in above-described embodiment as medium.
In figure: ordinary preparation refer to take Coated Aldehyde Oxystarch as effective ingredient, containing sodium alginate and albumin particle diameter by the preparation of 20 mesh sieves.
Above one embodiment of the present of invention are had been described in detail, but described content is only preferred embodiment of the present invention, can not be considered to for limiting practical range of the present invention.All equalization variations of doing according to the present patent application scope and improvement etc., within all should still belonging to patent covering scope of the present invention.
The specific embodiment
Embodiment 1: take Coated Aldehyde Oxystarch 650g, and sodium alginate 100g, human albumin 80g mix homogeneously, the sodium alginate aqueous solution 430ml with 1% grinds, surveys particle diameter, granulation, and freezer dryer is dried, and controls pellet moisture≤1%, makes granule
iamount to 848g.Get granule I 300g, add magnesium stearate 2.4g to mix, incapsulate, 0.625g/ grain, obtains 475 of Coated Aldehyde Oxystarch capsules.
Embodiment 2: take Coated Aldehyde Oxystarch 800g, sodium alginate 80g, human albumin 70g mix homogeneously, sodium alginate aqueous solution 410ml with 1% granulates, and grinds, surveys particle diameter, granulation, and freezer dryer is dried, control pellet moisture≤1%, make granule II and amount to 967g.Get granule II 400g, add Pulvis Talci 3g, incapsulate, 0.5g/ grain, obtains 790 of Coated Aldehyde Oxystarch capsules.
Embodiment 3: take Coated Aldehyde Oxystarch 500g, sodium alginate 200g, human albumin 130g, mix homogeneously, the sodium alginate aqueous solution 350ml with 1% grinds, surveys particle diameter, granulation, and freezer dryer is dried, control pellet moisture≤1%, make granule III and amount to 848g, get granule II 300g, magnesium stearate 3g, incapsulate, 0.5g/ grain, obtains 582 of Coated Aldehyde Oxystarch capsules.
Embodiment 4: the freezing kidney chronic kidney hypofunction of rat model, rat mercuric chloride kidney acute renal failure model, the capsule of feeding in the present invention, to feeding under these oral formulations 3 g preparation/100g body weight of administration, 1g preparation/100g body weight, 0.5g preparation/100g body weight dosage, every day 2 times, after continuous 1 week, blood biochemical detects rat blood serum blood urea nitrogen (BUN), creatinine (Scr) all has reduction (P < 0.05) in various degree, and in rat urine, protein content also obviously reduces (P < 0.05).Prompting said preparation can improve the development of various acute and chronic injury of kidney, the exhaustion of antagonism rat kidney.
Embodiment 5: the freezing kidney chronic failure of rat model is divided into groups, single gives the preparation of Isodose (3g preparation/100g body weight), wherein administration group I is this nanoscale oral formulations, administration group II is Coated Aldehyde Oxystarch common oral preparation, set blank group simultaneously, respectively at 1 hour, 4 hours, 8 hours, 24 hours, within 48 hours, obtain rat blood sample and urine sample, detection display, with the comparison of blank group, 1 hour and 4 hours BUN after the medication of two administration groups, Scr there was no significant difference (P > 0.05), 8 hours, 24 hours and 48 hours BUN, Scr all significantly reduces (P < 0.01), in 8 hours, twenty-four-hour urine liquid, protein content obviously reduces (P < 0.05), 48 hours protein content there was no significant differences (P > 0.05).Two administration groups compare mutually, 1 hour, 4 hours, 8 hours BUN, Scr there was no significant difference (P > 0.05) after medication, within 24 hours, 48 hours, BUN, Scr administration group I are starkly lower than administration group II (P < 0.05); No significant difference (P > 0.05) between day part urine protein content administration group I and administration group II.Prompting administration group I, all effectively development of antagonism chronic kidney hypofunction of II, its effectiveness administration group I is better than administration group II.
Embodiment 6: using methylene blue as indicator, adopting formulation preparation method of the present invention to prepare methylene blue content is 5% Coated Aldehyde Oxystarch slow release nanometer formulation (preparation A), prepares methylene blue content simultaneously and is all 5% Coated Aldehyde Oxystarch ordinary preparation (preparation B).Select body weight 220 ± 10g rat feed respectively preparation A and preparation B, set blank group simultaneously, observe and show that rat defecation condition is all normal, administration group, matched group all without constipation, be hard and dry, the situation such as difficult defecation occurs, the blue feces time of occurrence of rat is irregular distribution, it is suitable with matched group that preparation B group is taken in demonstration average time, takes preparation A group significantly than taking preparation B group and matched group length (P < 0.05).After 7 days, repeat above-mentioned experiment, within after administration 4 hours, put to death rat, peel off intestine in rats, measure pylorus to aobvious blue (or light blue) Front distance of intestinal, it is suitable with matched group that preparation B group is taken in result demonstration, takes preparation A group significantly than taking preparation B group and matched group short (P < 0.05).Through above-mentioned experiment, can think that the preparation that contains sodium alginate transports slower in intestinal.
Claims (6)
1. novel blood urea nitrogen solid absorption preparation and preparation method thereof, by containing Coated Aldehyde Oxystarch, human albumin, sodium alginate, and as soluble calcium salt, the aluminum salt solution of firming agent, is characterized in that:
The nano level preparation that described solid absorption preparation is slow release, described material proportion is:
Coated Aldehyde Oxystarch 50-60%
Human albumin is 1-30%
Sodium alginate 1-20%
Firming agent 0.5-1.0%.
2. a kind of novel blood urea nitrogen solid absorption preparation according to claim 1 and preparation method thereof, is characterized in that: native albumin or the biological method preparation of described human albumin for extracting, the purity of human albumin is greater than 99.9%.
3. a method of manufacturing a kind of novel blood urea nitrogen solid absorption preparation described in claim 1, is characterized in that: the ratio according to the material of setting is dissolved, and the material having dissolved is fully ground to particle size determination, lyophilizing.
4. lapping mode according to claim 3, is characterized in that: lapping mode can be selected one or several in cell grinder, Ultrasonic Cell Disruptor, cell crushing instrument, and material need grind above through 3 times, and operation should be carried out at low temperatures.
5. particle size determination according to claim 3, is characterized in that: ground material carries out the mensuration of nanometer particle size, and nanometer particle size reaches 20-50nm.
6. freeze drying process according to claim 3, is characterized in that: be positioned over-80 ℃ of refrigerators and carry out pre-freeze, then by freezer dryer, carry out the freezing of 72h left and right, finally form crystalloid powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310488516.0A CN103536909A (en) | 2013-10-18 | 2013-10-18 | Novel urea nitrogen solid adsorption preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310488516.0A CN103536909A (en) | 2013-10-18 | 2013-10-18 | Novel urea nitrogen solid adsorption preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103536909A true CN103536909A (en) | 2014-01-29 |
Family
ID=49961022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310488516.0A Pending CN103536909A (en) | 2013-10-18 | 2013-10-18 | Novel urea nitrogen solid adsorption preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103536909A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789337A (en) * | 2016-08-30 | 2018-03-13 | 天津太平洋制药有限公司 | A kind of new oxyamyli tectus aldehydum spansule and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1509144A (en) * | 2001-05-15 | 2004-06-30 | \ | Prebiotic and probiotic compositions and methods of use thereof in the treatment of intestinal disorders |
| CN101375858A (en) * | 2008-10-09 | 2009-03-04 | 天津太平洋制药有限公司 | Solid formulation of urea nitrogen sorbent for compensating kidney function and preparation method thereof |
-
2013
- 2013-10-18 CN CN201310488516.0A patent/CN103536909A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1509144A (en) * | 2001-05-15 | 2004-06-30 | \ | Prebiotic and probiotic compositions and methods of use thereof in the treatment of intestinal disorders |
| CN101375858A (en) * | 2008-10-09 | 2009-03-04 | 天津太平洋制药有限公司 | Solid formulation of urea nitrogen sorbent for compensating kidney function and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| TOSHIMI SHIMIZU等: "A newly prepared surface-treated oxystarch for removal of urea", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789337A (en) * | 2016-08-30 | 2018-03-13 | 天津太平洋制药有限公司 | A kind of new oxyamyli tectus aldehydum spansule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2242413T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASA INHIBITORS. | |
| US20040105895A1 (en) | Monovalent-selective cation exchangers as oral sorbent therapy | |
| CN102224896A (en) | Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof | |
| CN102512386A (en) | Amoxicillin or amoxicillin and clavulanate potassium instant chewable tablets for pet and preparation method for same | |
| JP5643227B2 (en) | Disintegrating preparation of lanthanum carbonate | |
| CN105407899B (en) | Composition for the treatment of progressive kidney disease | |
| CN103285374A (en) | Amoxicillin colistin sulphate granule and preparation method thereof | |
| CN101278929B (en) | Method for preparing medicament containing gambogic acid compounds and clathrate of gambogic acid compounds | |
| CN103536909A (en) | Novel urea nitrogen solid adsorption preparation and preparation method thereof | |
| CN101524355B (en) | Compound preparation of antituberculosis medicaments, and preparation method thereof | |
| CN101416966A (en) | Medical composition capable of treating hypertension | |
| CN105106164B (en) | A kind of fresh-water fishes coating Enrofloxacin micropill and preparation method thereof | |
| CN103800297B (en) | A kind of praziquantel composition in-stomach floating type sustained-release sheet and preparation method thereof | |
| CN107789337A (en) | A kind of new oxyamyli tectus aldehydum spansule and preparation method thereof | |
| CN104543662B (en) | A kind of production method of hypoglycemic coprinus comatus polyoses grain | |
| CN102871983A (en) | Gambogic acid colon-specific controlled release tablet and preparation method thereof | |
| CN101862320A (en) | Solid preparation of ranitidine hydrochloride/bismuth potassium citrate medicinal composition | |
| CN102813661B (en) | Application for glycyrrhetinic acid derivatives | |
| CN108294317A (en) | A kind of walnut peptide enteric-coated micro-pill and preparation method thereof | |
| CN102579407B (en) | Preparation method for indapamide microsphere sustained release capsules | |
| EP4181934A1 (en) | Crystalline zirconium phosphate for use in therapy, pharmaceutical composition, and use of the same | |
| CN108144063B (en) | Preparation method of pellet liquid-filled capsule with weight-losing and health-care functions | |
| US20170105979A1 (en) | Use of a torasemide-based veterinary composition for low-dose administering | |
| CN101375858A (en) | Solid formulation of urea nitrogen sorbent for compensating kidney function and preparation method thereof | |
| CN100508977C (en) | Slow release tablet of medetofazone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140129 |